Pharma BD Deal Intelligence
Octane Medical Group / B. Braun Melsungen AG
2024 · Asset Purchase · Complete
Octane Medical Group, through its Octane Biotherapeutics (BioTx) venture, acquired 100% of the shares of B. Braun's global orthobiologics business, comprising TETEC AG (Germany) and Aesculap Biologics, LLC (United States). The acquired platform includes the NOVOCART 3D and NOVOCART Inject autologous chondrocyte products for cartilage repair; deal value was not disclosed.
This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2029 at the earliest for this deal, once/if it closes.
Key facts
- Announced Jun 07, 2024
- Deal type Asset Purchase
Related deals
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals
More: 2024 deals